Australia’s active vaccine safety system

Publications

Filter

Publications

Tran H, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan C, Gold M, Hissaria P, Melody S, Chunilal S, Buttery J, Clothier H, Crawford N, Phuong L, Pepperell D, Effler P, Parker C, Carter N. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study. The Lancet Western Pacific. doi:10.1016/j.lanwpc.2023.100894. [Full text]

Deng L, Lopez L, Glover C, Cashman P, Reynolds R, Macartney K, Wood N. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox. JAMA. 2023;329(23):2091-2094. doi:10.1001/jama.2023.7683. [Full text]

Deng L, Glover C, Dymock M, Pillsbury A, Marsh JA, Quinn HE, Leeb A, Cashman P, Snelling TL, Wood N, Macartney K. The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Medical Journal of Australia. doi: 10.5694/mja2.51619. [Full text]

Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford C, Snelling TL, Durrheim D, Macartney K. Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance. BMJ Open. 2021;11:e043880 . [Abstract]

Totterdell J, Phillips A, Glover C, Chidwick K, Marsh J, Snelling T, Macartney K. Safety of live attenuated herpes zoster vaccine in adults 70 to 79 years: a self-controlled case series analysis using primary care data from the MedicineInsight program. Vaccine. 2020;38:3968-3979. [Abstract]

Glover C, Crawford N, Leeb A, Wood N, Macartney K. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety. Vaccine. 2020;38:4892-4900. [Abstract]

Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney K . Comparative post-market safety profile of adjuvanted and high-dose influenza vaccines in the elderly. JAMA Open. 2020;3(5):e204079 . [Full text]

Jacoby P, Glover C, Damon C, Fathima P, Pillsbury A, Durrheim D, Gold M, Leeb A, Snelling T. Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study. BMJ Open 2020;10:e031851 . [Full text]

P. Cashman, S. Moberley, K. Chee, J. Stephenson, S. Chaverot, J. Martinelli, T. Gadsden, C. Bateman-Steel, L. Redwood, Z. Howard, M.J. Ferson and D.N. Durrheim. Participant centred safety surveillance of health care workers receiving influenza vaccination. Vaccine 2019;37:2427-2429. [Abstract]

Crawford NW, Hodgson K, Gold M, Buttery J, Wood N. Adverse evens following HPV immunisation in Australia: establishment of a clinical network. Human Vaccines and Immunotherapeutics 2016;12:2662-5. [Full text]

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433  |  Fax (612) 9845 1418  |  ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Copyright © 2022 AusVaxSafety. All rights reserved

vaccine

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433  |  Fax (612) 9845 1418  |  ABN 53 188 579 090

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.